title: Response to Lertxundi and colleagues.
authors.affiliation: University of South Australia, Adelaide, SA, Australia.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Kalisch Ellett
authors.affiliation: University of South Australia, Adelaide, SA, Australia.
authors.forename: Nicole L
authors.initials: NL
authors.lastname: Pratt
authors.affiliation: University of South Australia, Adelaide, SA, Australia.
authors.forename: Emmae N
authors.initials: EN
authors.lastname: Ramsay
authors.affiliation: University of South Australia, Adelaide, SA, Australia.
authors.forename: John D
authors.initials: JD
authors.lastname: Barratt
authors.affiliation: University of South Australia, Adelaide, SA, Australia.
authors.forename: Elizabeth E
authors.initials: EE
authors.lastname: Roughead
mesh_terms: D018680:Cholinergic Antagonists / Q000009:adverse effects*; D003221:Confusion / Q000139:chemically induced* / Q000453:epidemiology*; D003704:Dementia / Q000139:chemically induced* / Q000453:epidemiology*; D005260:Female; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male
chemical_list: D018680:Cholinergic Antagonists